- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-3170
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Glycaemic Effects of Non-statin Lipid-Lowering Therapies ; volume:18 ; number:12 ; day:19 ; month:11 ; year:2016 ; pages:1-5 ; date:12.2016
Current cardiology reports ; 18, Heft 12 (19.11.2016), 1-5, 12.2016
- Creator
-
Collins, Patrick D.
- Contributor
-
Sattar, Naveed
SpringerLink (Online service)
- DOI
-
10.1007/s11886-016-0795-9
- URN
-
urn:nbn:de:1111-201612227243
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Collins, Patrick D.
- Sattar, Naveed
- SpringerLink (Online service)
Other Objects (12)
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression
Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression
Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression
Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C